BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15459145)

  • 1. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
    Wasserfallen JB; Erard V; Cometta A; Calandra T; Lamy O
    Eur Respir J; 2004 Oct; 24(4):644-8. PubMed ID: 15459145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
    Mokabberi R; Haftbaradaran A; Ravakhah K
    J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
    Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
    Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP; Matchar DB; Harnett J; Wilson J
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
    Erard V; Lamy O; Bochud PY; Bille J; Cometta A; Calandra T
    Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):82-8. PubMed ID: 14727149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
    File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
    Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
    Bergallo C; Jasovich A; Teglia O; Oliva ME; Lentnek A; de Wouters L; Zlocowski JC; Dukart G; Cooper A; Mallick R;
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):52-61. PubMed ID: 18990531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
    Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of levofloxacin versus cefuroxime axetil in the outpatient treatment of adults with community-acquired pneumonia.
    Rittenhouse BE; Stinnett AA; Dulisse B; Henke CJ; Potter L; Parasuraman B; Martens LL; Williams RR; Kojak C
    Am J Manag Care; 2000 Mar; 6(3):381-9. PubMed ID: 10977438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A; Holman A; Evers T
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
    Clark LC; Davis CW
    Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin in the treatment of community-acquired pneumonia.
    Noreddin AM; Elkhatib WF
    Expert Rev Anti Infect Ther; 2010 May; 8(5):505-14. PubMed ID: 20455679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, randomized comparison of levofloxacin and amoxicillin/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia.
    Lin TY; Lin SM; Chen HC; Wang CJ; Wang YM; Chang ML; Wang CH; Liu CY; Lin HC; Yu CT; Hsieh LL; Kuo HP; Huang CD
    Chang Gung Med J; 2007; 30(4):321-32. PubMed ID: 17939262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Levofloxacin versus beta-lactamic therapy in community acquired pneumonia that requires hospitalization].
    Geijo Martínez MP; Díaz de Tuesta Chow-Quan AM; Herranz CR; Gómez Criado C; Dimas Nuñez JF; Saiz García F
    An Med Interna; 2002 Dec; 19(12):621-5. PubMed ID: 12593029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.